Published in Diabetes Care on April 14, 2009
A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin. | NCT00423501
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care (2011) 1.63
Incretin-based therapies. J Diabetes (2012) 1.48
Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol (2010) 1.23
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord (2010) 1.14
Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. Diabetologia (2011) 1.05
Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) (2013) 1.04
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med (2010) 0.98
Obesity treatment: novel peripheral targets. Br J Clin Pharmacol (2009) 0.95
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol (2009) 0.95
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther (2011) 0.93
Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther (2012) 0.87
Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab (2013) 0.87
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care (2012) 0.85
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Open Med Chem J (2011) 0.84
Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther (2015) 0.84
Incretin therapy--present and future. Rev Diabet Stud (2011) 0.84
Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) (2012) 0.83
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag (2009) 0.83
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. Diabetes Care (2011) 0.82
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.81
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes Metab Syndr Obes (2010) 0.81
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care (2012) 0.81
Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure. J Diabetes Investig (2010) 0.80
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2010) 0.78
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS One (2016) 0.77
Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes Metab Syndr Obes (2010) 0.76
The evolving world of GLP-1 agonist therapies for type 2 diabetes. Ther Adv Endocrinol Metab (2010) 0.75
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. Clin Med Ther (2009) 0.75
Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials. Saudi Pharm J (2014) 0.75
Incretin concepts. Diabetes Care (2010) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care (2003) 6.63
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care (2008) 5.94
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care (2006) 4.75
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 3.72
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol (1999) 1.77
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab (1993) 1.61
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol (1999) 1.60
Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med (2008) 1.46
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev (2004) 1.43
Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia (1996) 1.08
Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab (2003) 1.02
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A (2003) 17.10
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care (2004) 4.17
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 3.72
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes (2004) 3.66
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes (2004) 2.86
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes (2003) 2.63
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care (2011) 2.60
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA (2005) 2.58
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology (2007) 2.50
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care (2007) 2.20
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab (2010) 2.05
Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes (2005) 1.96
Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol (2009) 1.93
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care (2010) 1.59
Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol Endocrinol Metab (2008) 1.53
Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother (2006) 1.51
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care (2006) 1.51
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care (2007) 1.46
Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism (2004) 1.44
Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes (2006) 1.41
Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care (2011) 1.26
Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab (2004) 1.24
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab (2004) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.22
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther (2011) 1.21
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther (2011) 1.21
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care (2010) 1.19
Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care (2013) 1.18
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract (2012) 1.16
Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Ther (2011) 1.14
Impact of computer-generated personalized goals on HbA(1c). Diabetes Care (2002) 1.14
The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care (2006) 1.11
Scientific statement: Socioecological determinants of prediabetes and type 2 diabetes. Diabetes Care (2013) 1.09
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J (2006) 1.08
Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab (2006) 1.03
PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY. J Clin Lipidol (2009) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care (2009) 1.01
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol (2004) 1.01
Global relationship between the proteome and transcriptome of human skeletal muscle. J Proteome Res (2008) 0.99
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care (2012) 0.96
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther (2008) 0.93
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry (2009) 0.93
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev (2009) 0.93
Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc (2013) 0.92
Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J Diabetes Sci Technol (2012) 0.92
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2002) 0.90
Gestational diabetes mellitus in Sardinia: results from an early, universal screening procedure. Diabetes Care (2006) 0.89
Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear. Drug Deliv Transl Res (2015) 0.89
Increased insulin receptor signaling and glycogen synthase activity contribute to the synergistic effect of exercise on insulin action. J Appl Physiol (1985) (2003) 0.88
Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther (2012) 0.87
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving! Diabetes Care (2014) 0.86
Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. Comput Methods Programs Biomed (2007) 0.86
Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism (2013) 0.86
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care (2012) 0.85
Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. Am J Physiol Endocrinol Metab (2002) 0.84
The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med (2003) 0.83
Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am (2005) 0.83
The American Diabetes Association diabetes research perspective. Diabetes (2012) 0.82
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes (2002) 0.82
A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging. Magn Reson Imaging (2003) 0.82
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging (2011) 0.82
The American Diabetes Association diabetes research perspective. Diabetes Care (2012) 0.81
Effects of microdialysis catheter insertion into the subcutaneous adipose tissue assessed by the SCGM1 system. Diabetes Technol Ther (2003) 0.81
Correlation between anthropometric parameters and abdominal fat volumes assessed by a magnetic resonance imaging method in patients with diabetes. Diabetes Technol Ther (2004) 0.81
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care (2012) 0.81
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. Diabetes Technol Ther (2013) 0.80
Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study. Clin Endocrinol (Oxf) (2010) 0.80
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab (2012) 0.80
Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring) (2013) 0.80
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. J Diabetes Complications (2011) 0.80
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab (2015) 0.79
Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep (2011) 0.79
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. J Hypertens (2016) 0.79
Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery. Obesity (Silver Spring) (2008) 0.79
Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care (2002) 0.78
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol (2006) 0.78
Autoimmunity in gestational diabetes mellitus in Sardinia: a preliminary case-control report. Reprod Biol Endocrinol (2008) 0.78
Pramlintide: A new tool in diabetes management. Curr Diab Rep (2006) 0.78
Managing people at high risk for diabetes. Ann Intern Med (2006) 0.77
Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol (2006) 0.77